---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-037183"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:21:22.103657+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Absci Q2 2024: revenue $1.3M, net loss $24.8M; ABS-101 half-life 2-3x; MSK collab

## Summary
- Q2 revenue $1.3M (down from $3.4M YoY); net loss $24.8M vs $41.7M (incl. $21.3M non-cash impairment in prior year).
- Cash, cash equivalents and short-term investments $145.2M; expects runway into H1 2027.
- ABS-101 NHP data: 2-3x extended half-life vs clinical anti-TL1A antibodies; 200 mg/mL formulation supports subcutaneous.
- Entered collaboration with Memorial Sloan Kettering to co-develop up to 6 novel oncology therapeutics using generative AI.
- Anticipates Phase 1 start for ABS-101 in early 2025; interim data readout expected H2 2025.

## SEC filing metadata
- accession: 0001628280-24-037183
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828024037183/0001628280-24-037183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828024037183/absc-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-037183
- JSON: https://secwatch.observer/filing/0001628280-24-037183.json
- Plain text: https://secwatch.observer/filing/0001628280-24-037183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.